BLA 125103 · Biovitrum Ab
Kepivance
Palifermin · Injection · Mucocutaneous Epithelial Cell Growth Factor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 15, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
60
8 Phase 3, 5 recruiting
FAERS reports
389
351 serious, 67 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 17, 2025.
Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. ( 1.1 ) Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies ( 1.2 , 5.1 ) Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. ( 1.2 , 14.3 ) Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen ( 14.2 ). 1.1 Indications Kepivance is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. 1.2 Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic...
Mechanism: KGF is an endogenous protein in the fibroblast growth factor (FGF) family that binds to the KGF receptor. Binding of KGF to its receptor has been reported to result in proliferation, differentiation, and migration of epithelial cells. The KGF receptor, one of four receptors in the FGF family, has been reported to be present on epithelial cells in many tissues examined including the tongue, buccal mucosa, esophagus, stomach, intestine, salivary gland, lung, liver, pancreas, kidney, bladder, mammary gland, skin (hair follicles and sebaceous gland), and the lens of the eye. The KGF receptor has...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 14, 2011 Supplement 120 · Efficacy LabelLetter
- Dec 15, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewPediatric Medical Review
1 products under this application
- KEPIVANCE · PALIFERMIN 60MCG/KG/DAY · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palifermin" as an intervention, any sponsor and status, largest first.
Center for International Blood and Marrow Transplant ResearchResearch network
NCT06859424 · 358 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2028
Drug: Conditioning Regimen A; Conditioning Regimen B and 12 more · For: AML (Acute Myelogenous Leukemia); Acute Lymphoid Leukemia (ALL); Acute Leukemia (Category) and 8 more
Sites: Birmingham, Alabama; Duarte, California; Palo Alto, California · 13 sites in all
- A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple MyelomaPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT00434161 · 281 participants · Start Dec 2006 · Primary completion Mar 2009
Drug: Palifermin before only; Placebo and 1 more · For: Multiple Myeloma
Sites: Leipzig, Germany
- A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00131638 · 241 participants · Start Jan 2005 · Primary completion Nov 2007
Drug: Placebo; Palifermin · For: Head and Neck Cancer
- Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck CancerPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT00101582 · 188 participants · Start Aug 2005 · Primary completion Sep 2007
Drug: Placebo; palifermin and 1 more · For: Mucositis; Solid Tumors; Stomatitis and 2 more
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) TransplantationPivotal-lookingCompleted
Swedish Orphan BiovitrumIndustry
NCT00189488 · 155 participants · Start Dec 2005 · Primary completion Nov 2008
Drug: Palifermin; Placebo and 1 more · For: Graft Versus Host Disease; Hematologic Malignancies
Swedish Orphan BiovitrumIndustry
NCT00352703 · 145 participants · Start Apr 2006 · Primary completion Apr 2007
Drug: Kepivance (Palifermin) · For: Non-Hodgkin's Lymphoma; Multiple Myeloma
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00410982 · 145 participants · Start Dec 2006 · Primary completion Sep 2012
Drug: Busulfan; Gemcitabine and 3 more · For: Leukemia; Lymphoma; Myeloma
Sites: Houston, Texas
- Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerPivotal-lookingCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT00004061 · 111 participants (planned) · Start May 1999 · Primary completion May 2003
Drug: filgrastim; palifermin and 3 more · For: Leukemia; Lymphoma; Oral Complications
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- mucosal inflammation56
- febrile neutropenia39
- rash39
- stomatitis34
- erythema28
- sepsis24
- pyrexia23
- diarrhoea20
- neutropenia20
- infection19
- oedema peripheral19
- off label use19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 23 |
| 2006 | 60 |
| 2007 | 60 |
| 2008 | 55 |
| 2009 | 17 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 4 |
| 2015 | 19 |
| 2016 | 19 |
| 2017 | 47 |
| 2018 | 16 |
| 2019 | 8 |
| 2020 | 11 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis.
Daugulaitu G, Užkuraitytu K, Jagelavičienu E, et al. · Medicina (Kaunas) 2019 · Systematic Review
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Keratinocyte growth factor impairs human thymic recovery from lymphopenia.
Coles AJ, Azzopardi L, Kousin-Ezewu O, et al. · JCI Insight 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
Goldberg JD, Zheng J, Castro-Malaspina H, et al. · Bone Marrow Transplant 2013 · Clinical Trial, Phase II, Comparative Study
- Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR, Pritchard MW, Thomas CM, et al. · Cochrane Database Syst Rev 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy.
Coutsouvelis J, Corallo C, Spencer A, et al. · Crit Rev Oncol Hematol 2022 · Meta-Analysis, Review
Sponsor: Biovitrum Ab
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.